Tori Erxleben Rush, PharmD Selected to Return as PQA Panel Co-Chair in 2025
Tori Erxleben Rush, PharmD
Product Director, RxAnte
The Pharmacy Quality Alliance (PQA) has selected Tori Erxleben Rush, PharmD to return as co-chair for the Quality Measure Expert Panel (QMEP) for another year. Dr. Erxleben Rush will be continuing her second term on the QMEP and will remain on the panel until the end of 2027. As Director of clinical pharmacy programs, Dr. Erxleben Rush uses her expertise on measure performance to provide insight on recommended changes to quality measures as proposed by PQA. As co-chair, Erxleben Rush will present updates and facilitate discussions within the QMEP and help advance PQA’s mission to optimize health by advancing the quality of medication use.
PQA Quality Metrics Expert Panel (QMEP)
The QMEP is a select group of approximately 25 PQA members who assess measures in development and maintenance against standard measure criteria, make final recommendations to PQA membership regarding measure endorsement or retirement consideration, and make final recommendations to PQA staff for measure development discontinuation.
New QMEP members will serve a three-year term (2025-2027) with the option to serve a second term, and were chosen based on their measure development experience or other subject matter expertise (e.g., clinical, analytic, measurement science, quality improvement), as well as considerable experience participating in PQA groups.
The MUP and QMEP are standing PQA panels that meet monthly or, as needed, via webinar and will convene starting in January 2025.
Read more on PQA’s post about the appointed individuals serving on the panels: PQA Appoints Individuals to Serve on 2025 Panels
Related Resources
01-08-2019
Hard Questions MAPD Plans Need to Ask for the 2020 Star Ratings Year
In the face of CMS’s proposed changes to everything from cut points to quality measures, Medicare Advantage Part D (MAPD) plans are asking themselves some hard questions about their 2020 Star Ratings programs. We asked Deborah O’Connor, RxAnte’s Director of Business Development, for the answers.
01-22-2019
Top Three Ways MAPD Star Ratings Strategies Fail
If you’re a Medicare Advantage Part D (MAPD) health plan, your Star Ratings strategy can make or break you (and your bonus dollars). Here are some less obvious ways we see MAPD plans not meeting their Star Ratings potential.
02-27-2019
Polypharmacy & Deprescribing – A Plan of Attack for MAPD Plans, Providers, & Pharmacists
Polypharmacy is a problem that belongs to all of us in the healthcare industry, which is why we need to address it together. If we want to really solve it, we’ll have to use analytics the way it was intended – leveraged as a powerful tool in a systematic approach.